Albumedix and Hebei Changshan Biochem Pharma have entered into a supply agreement for the development of a novel type II diabetes treatment that enables once-weekly dosing. The agreement will see Albumedix’s recombinant albumin based half-life extension platform used for the development and later commercialization of a modified glucagon-like-peptide albumin conjugate (Albenatide) for the treatment of patients living with the condition in China.